{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:46:07Z","timestamp":1792161967088,"version":"4.4.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chlorothiazide (CLTZ) is among the most commonly prescribed diuretics for preterm infants with bronchopulmonary dysplasia, yet no contemporary pharmacokinetic (PK) data inform its dosing in this population. Traditional plasma assays require blood volumes that are infeasible in neonates, limiting PK research. Volumetric absorptive microsampling (VAMS) enables fixed-volume whole-blood collection at minimal sampling burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We developed and validated a liquid chromatography\u2013tandem mass spectrometry assay for quantification of CLTZ in 10-\u00b5L whole-blood samples collected with Mitra VAMS devices. Validation followed FDA bioanalytical guidelines and included accuracy, precision, selectivity, matrix effects, recovery, dilution integrity, hematocrit (HCT) impact, and stability. Clinical feasibility was assessed in infants receiving enteral CLTZ as part of routine care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The assay was linear from 10 to 10,000 ng\/mL (R &gt; 0.99). Accuracy and precision met acceptance criteria at all quality control levels, with bias within 2% and maximum coefficient of variation (CV) of 16% at the lower limit of quantification (LLOQ) (10 ng\/mL). HCT values from 20% to 60% did not affect performance (bias \u226411%, CV \u22647%). Dilution integrity was preserved with 20-fold dilution, and interference from hydrochlorothiazide was below the LLOQ. CLTZ was stable on VAMS tips for 1 day at room temperature and refrigeration, 63 days at \u221220\u00b0C, 187 days at \u221280\u00b0C, and through 3 freeze\u2013thaw cycles. In clinical samples from 5 infants, concentrations ranged from approximately 200 to 4800 ng\/mL and declined as expected after dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This validated VAMS liquid chromatography\u2013tandem mass spectrometry assay accurately quantifies CLTZ from very small blood volumes with minimal HCT sensitivity and robust stability, supporting rigorous PK and exposure\u2013response studies in preterm and critically ill infants.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001524","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:00:10Z","timestamp":1792159210000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Development and Validation of a Chlorothiazide Whole-Blood Microsampling Assay"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7435-2610","authenticated-orcid":false,"given":"Timothy D.","family":"Nelin","sequence":"first","affiliation":[{"name":"Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Bruton","sequence":"additional","affiliation":[{"name":"Small Molecule and Metabolite Core Laboratory, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Pediatric Pharmacotherapy Innovation Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Downes","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Clinical Futures, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Pediatric Pharmacotherapy Innovation Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A.","family":"Bamat","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Clinical Futures, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Pediatric Pharmacotherapy Innovation Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"R2-20261016","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpeds.2021.08.075","article-title":"Medication use in the neonatal intensive care unit and changes from 2010 to 2018","volume":"240","author":"Stark","year":"2022","journal-title":"J Pediatr"},{"key":"R3-20261016","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/ajh\/hpac048","article-title":"Thiazide and the thiazide-like diuretics: review of hydrochlorothiazide, chlorthalidone, and indapamide","volume":"35","author":"Ernst","year":"2022","journal-title":"Am J Hypertens"},{"key":"R4-20261016","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41572-019-0127-7","article-title":"Bronchopulmonary dysplasia","volume":"5","author":"Th\u00e9baud","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20261016","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41372-021-00924-y","article-title":"The association between diuretic class exposures and enteral electrolyte use in infants developing grade 2 or 3 bronchopulmonary dysplasia in United States children's hospitals","volume":"41","author":"Nelin","year":"2021","journal-title":"J Perinatol"},{"key":"R8-20261016","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jcph.1739","article-title":"Pharmacokinetics of hydrochlorothiazide in children: a potential surrogate for renal secretion maturation","volume":"61","author":"Commander","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"R9-20261016","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/bdd.2510030202","article-title":"Bioavailability of chlorothiazide from 50, 100, and 250 mg solution doses","volume":"3","author":"Osman","year":"1982","journal-title":"Biopharm Drug Dispos"},{"key":"R10-20261016","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/jps.23491","article-title":"Chlorothiazide is a substrate for the human uptake transporters OAT1 and OAT3","volume":"102","author":"Juh\u00e1sz","year":"2013","journal-title":"J Pharm Sci"},{"key":"R12-20261016","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4155\/bio-2022-0063","article-title":"A whole blood microsampling furosemide assay: development, validation and use in a pediatric pharmacokinetic study","volume":"14","author":"Bamat","year":"2022","journal-title":"Bioanalysis"},{"key":"R13-20261016","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.3390\/molecules28166046","article-title":"Analytical and clinical validation of assays for volumetric absorptive microsampling (VAMS) of drugs in different blood matrices: a literature review","volume":"28","author":"Nugraha","year":"2023","journal-title":"Molecules"},{"key":"R15-20261016","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1021\/ac60052a025","article-title":"Simplified statistics for small numbers of observations","volume":"23","author":"Dean","year":"1951","journal-title":"Anal Chem"},{"key":"R16-20261016","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clp.2011.12.007","article-title":"Neonatal diuretic therapy: furosemide, thiazides, and spironolactone","volume":"39","author":"Segar","year":"2012","journal-title":"Clin Perinatol"},{"key":"R17-20261016","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1002\/ppul.27223","article-title":"Bronchopulmonary dysplasia and diuretic use in an outpatient setting","volume":"59","author":"McGlynn","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"R18-20261016","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1681\/ASN.2010121266","article-title":"Accelerated maturation and abnormal morphology in the preterm neonatal kidney","volume":"22","author":"Sutherland","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R19-20261016","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/mol.110.070680","article-title":"Functional maturation of drug transporters in the developing, neonatal, and postnatal kidney","volume":"80","author":"Sweeney","year":"2011","journal-title":"Mol Pharmacol"},{"key":"R21-20261016","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1310\/hpj4402-129","article-title":"A review of critical differences among loop, thiazide, and thiazide-like diuretics","volume":"44","author":"Min","year":"2009","journal-title":"Hosp Pharm"},{"key":"R22-20261016","doi-asserted-by":"crossref","first-page":"113102","DOI":"10.1016\/j.jpba.2020.113102","article-title":"Opportunities and obstacles for microsampling techniques in bioanalysis: special focus on DBS and VAMS","volume":"182","author":"Londhe","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"R24-20261016","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1248\/bpb1978.12.423","article-title":"Binding of hydrochlorothiazide to erythrocytes","volume":"12","author":"Yamazaki","year":"1989","journal-title":"J Pharmacobiodyn"},{"key":"R25-20261016","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/cpt1975174424","article-title":"Binding\u2010site interaction of chlorthalidone and acetazolamide, two drugs transported by red blood cells","volume":"17","author":"Beermann","year":"1975","journal-title":"Clin Pharmacol Ther"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:00:12Z","timestamp":1792159212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":18,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001524","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"2026-04-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}